Successful sequential tyrosine kinase inhibitors to overcome a rare compound of EGFR exon 18–18 and EGFR amplification: A case report

BACKGROUND: New mutational detection techniques like next-generation sequencing have resulted in an increased number of cases with uncommon mutation and compound mutations [3%–14% of all epidermal growth factor receptor (EGFR) mutations]. In rare exon 18 mutations (3%–6%), G719X and E709X represent...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Pascal, Fabre, Emmanuelle, Martin, Antoine, Chouahnia, Kader, Benabadji, Ambre, Matton, Lise, Duchemann, Boris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358716/
https://www.ncbi.nlm.nih.gov/pubmed/35957870
http://dx.doi.org/10.3389/fonc.2022.918855

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358716/
https://www.ncbi.nlm.nih.gov/pubmed/35957870
http://dx.doi.org/10.3389/fonc.2022.918855

Ejemplares similares